20:34 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Mereo postpones NASDAQ listing

Mereo BioPharma Group plc (LSE:MPH) said on April 26 it postponed an offering to list its ADSs on NASDAQ and withdrew a concurrent placing, citing market conditions. According to an April 9 SEC filing, the company...
20:05 , May 12, 2017 |  BC Week In Review  |  Clinical News

Mereo starts Phase IIb for osteogenesis imperfecta

Mereo BioPharma Group plc (LSE:MPH) began the Phase IIb ASTEROID trial to evaluate BPS-804 to treat osteogenesis imperfecta. The double-blind, placebo-controlled, international trial will enroll up to 120 patients to receive 1 of 3 doses...
22:59 , Mar 2, 2017 |  BC Week In Review  |  Clinical News

BPS-804 regulatory update

EMA selected for its adaptive pathways program BPS-804 from Mereo to treat osteogenesis imperfecta (OI). The human mAb inhibiting sclerostin has Orphan Drug designation in the U.S. and EU and has completed Phase II testing...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

Novartis, Mereo BioPharma deal

Start-up Mereo acquired three Phase II compounds from Novartis in exchange for an undisclosed equity stake. Novartis is eligible for milestone payments and royalties. BPS-804 is a human mAb for the Orphan bone disease...
07:00 , Aug 3, 2015 |  BioCentury  |  Finance

From Phase4 to Mereo

The leadership team behind Phase4 Ventures is branching out from its traditional venture roots to launch newco Mereo BioPharma Group Ltd., which aims to provide an alternative for pharmas looking to advance mid-stage pipelines in...
01:07 , Jul 30, 2015 |  BC Extra  |  Top Story

Mereo raises $119M, acquires three Novartis programs<span class="*Red-type+bold">

Mereo BioPharma Group Ltd. (London, U.K.) debuted on Wednesday with $119 million (L76.7 million) and three clinical-stage programs acquired from Novartis AG (NYSE:NVS; SIX:NOVN). Woodford Investment Management and Invesco Perpetual invested in Mereo; Novartis also...